Generic Biologics Bill From Waxman Offers Tax Incentives For Studies On Interchangeability
This article was originally published in The Pink Sheet Daily
Executive Summary
Bill permits comparable products as long as they have no clinically meaningful differences and share the "principal molecular structure features" as innovators.